Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) Investor Files Lawsuit Over Alleged Breaches Of Fiduciary Duties In Connection With The Proposed Takeover By Bristol-Myers Squibb

If you purchased shares of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) prior to June 29, 2012, and currently hold any of those NASDAQ:AMLN shares, you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Amylin Pharmaceuticals
Case Name: 
Amylin Pharmaceuticals Deal Case 07/06/2012
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: AMLN
Lawsuit Overview
Type of Lawsuit: 
Mergers and Acquisition
Date Filed: 
07/06/2012
Summary: 

July 9, 2012 (Shareholders Foundation) -- An investor in NASDAQ:AMLN shares filed a lawsuit in State Court in effort to block the proposed takeover of Amylin Pharmaceuticals, Inc. at $31 per NASDAQ:AMLN share.

The plaintiff alleges that certain directors of Amylin Pharmaceuticals, Inc. breached their fiduciary duties owed NASDAQ:AMLN investors arising out of the attempt to sell the company too cheaply and via an unfair process to Bristol-Myers Squibb.

On June 29, 2012, after the market closed, Bristol-Myers Squibb Company (NYSE: BMY) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

However, the plaintiff alleges that the $31offer is unfair to NASDAQ:AMLN stockholders and undervalues the company. In fact, shares of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) grew from as low as $6.05 in November 2008 to as high as $28.21 per share on May 29, 2012. In addition, at least one analyst has set the high target price for NASDAQ:AMLN shares at $32 per share.